Psilocybin Research


A U.K. study published in the Journal of Psychopharmacology suggested that when given to patients with treatment resistant depression, psilocybin affected

“functional connectivity” changes in the brain which was evident in scans.

The study suggested that “psilocybin therapy improves how the brain works and revives emotional responsiveness.”

Other research is examining the benefits of microdosing,
which uses small doses of psilocybin to treat anxiety and depression.
A landmark study conducted by the Beckley/Imperial Research Program
has provided clinical evidence for the efficacy of psilocybin assisted
psychotherapy to treat depression, even in cases where all other
treatments have failed. Beckley Foundation Psilocybin for Depression.
In November, 2020, John Hopkins released results of a recent study showing psilocybin
as a powerful antidepressant. Researchers found two separate doses of psilocybin, combined with 11 hours of therapy in the weeks before and
after taking the drug, reduced depression symptoms in 71% of people.
More than half of the participants (54%) were considered to be in
remission for their depression four weeks post treatment.